These results provide compelling preclinical evidence for application of copanlisib in advanced MCC with aberrant PI3K activation for which immunotherapy is insufficient, or patients who are unsuitable for immunotherapy. The gene discussed is PIK3CB; the disease is Merkel cell skin cancer.